CYP2C9

Across TCGA pan-cancer cohorts, CYP2C9 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of CYP2C9’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where CYP2C9 RNA is repressed in tumor relative to normal tissue. In most cancer types CYP2C9 is over-expressed in tumor, although a few such as LIHC and KICH show the opposite, repressed pattern.

LIHC, KICH, and KIRP are the cancer types where CYP2C9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP2C9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	−3.522	<.001	8	view →
KICH	All	II,III,IV	−0.701	<.001	8	view →
KIRP	All	All	+0.825	<.001	7	view →
HNSC	All	All	−0.286	.021	6	view →
CHOL	Male	All	−5.265	<.001	5	view →
PAAD	All	All	+2.107	.014	2	view →
COAD	All	III,IV	−0.416	.026	1	view →
BRCA	All	All	−0.036	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

CYP2C9–LIHC

Open the LIHC breakdown →